source Post navigation Expert: Approval of Semaglutide Major Advancement for CKD, Cardiovascular Risk Reduction in Type 2 Diabetes – Pharmacy Times Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease–mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease – CMAJ
